Fick-BrosnahanG.M., TranZ.V., JohnsonA.M., StrainJ.D., GabowP.A.Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int2001; 59: 1654–62.
2.
RizkD., JurkovitzC., VeledarE.. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol2009; 4: 560–6.
ValvoE., GammaroL., TessitoreN.. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations. Am J Nephrol1985; 5: 176–81.
5.
ChapmanA.B., Guay-WoodfordL.M., GranthamJ.J.. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int2003; 64: 1035–45.
6.
ChapmanA.B., JohnsonA., GabowP.A., SchrierR.W.The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med1990; 323: 1091–6.
7.
ChapmanA.B., JohnsonA.M., GabowP.A., SchrierR.W.Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol1994; 5: 1349–54.
8.
EttingerA., KahnP.C., WiseH.M.Jr.. The importance of selective renal angiography in the diagnosis of polycystic disease. J Urol1969; 102: 156–61.
9.
EckardtK.U., MöllmannM., NeumannR.. Erythropoietin in polycystic kidneys. JCI1989; 84: 1160–66.
10.
DoultonT.W., Saggar-MalikA.K., HeF.J.. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens2006; 24: 939–45.
11.
GrahamP.C., LindopG.B.The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int1988; 33: 1084–90.
12.
Loghman-AdhamM., SotoC.E., InagamiT., CassisL.The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol2004; 287: F775–F788.
13.
HarrapS.B., DaviesD.L., MacnicolA.M.. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int1991; 40: 501–8.
14.
GattoneVH2nd, SiqueiraT.M.Jr., PowellC.R., TrambaughC.M., LingemanJ.E., ShalhavA.L.Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med2008; 233: 952–57.
15.
CerasolaG., VecchiM., MulèG.. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol1998; 18: 391–98.
16.
KleinI.H., LigtenbergG., OeyP.L., KoomansH.A., BlankestijnP.J.Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol2001; 12: 2427–33.
17.
EcderT., EdelsteinC.L., Fick-BrosnahanG.M.. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol2001; 21: 98–103.
18.
MaschioG., AbertiD., JaninG.. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med1996; 334: 939–45.
19.
KlahrS., BreyerJ.A., BeckG.J., DennisV.W., HartmanJ.A., RothD., SteinmanTI<, WangS.R., YamamotoM.E.Dietary protein restriction, blood pressure control and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol1995; 5(12): 2037–47.
20.
JafarT., StarkP.C., SchmidC.H., StandgaardS., KamperA., MaschioG., BeckerG., PerroneR.D., LeveyA.The effect of angiotensin-converting enzyme inhibitors on progression of polycystic kidney disease (PKD)Kidney Int2005; 6(1): 265–71.
21.
SchrierR., McFannK., JohnsonA.. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol2002; 13: 1733–39.
22.
NutaharaK., HigashiharaE., HorieS.. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract2005; 99: c18–23.
23.
McPhersonE.A., LuoZ., BrownR.A.. Chymase-like angiotensin Il-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol2004; 15: 493–500.
24.
ChapmanA.B., TorresV.E., PerroneR.D.. The HALT Polycystic Kidney Disease Trials - Design and Implementation. Clin J Am Soc Nephrol2010; 5: 102–09.
25.
BoulterC., MulroyS., WebbS., FlemingS., BrindleK., SandfordR.Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA.2001; 98: 12174–79.
26.
HassaneS., ClaijN., Lantinga-van LeeuwenI.S.. Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model. Arterioscler Thromb Vasc Biol2007; 27: 2177–83.
27.
WangD., IversenJ., WilcoxC.S., StrandgaardS.Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int2003; 64: 1381–88.
28.
NauliS.M., KawanabeY., KaminskiJ.J., PearceW.J., IngberD.E., ZhouJ.Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation2008; 117: 1161–71.
